The content on this site is intended for healthcare professionals only
Prof Josef Vormoor talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about the management of relapsed T-ALL in paediatrics.
Prof Vormoor explains that one of the clinical questions currently is that: if you inhibit the RAS pathway in patients with gene mutations and combine this with dexamethasone, do we see a signal that allows us to progress with more frontline treatment?
He outlines that this trial with the RAS pathway is open to children.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Multiple myeloma In Rwanda: The need for further research
More effective treatment options required for patients with MM post lenalidomide exposure
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
Relapsed refractory multiple myeloma
Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma
ADCLEC.syn1 and CD33-CARS in humanised acute myeloid leukaemia models shows promising efficacy
Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens
Nivolumab-AVD reduces the risk of disease progression compared to brentuximab vedotin-AVD in advanced Hodgkin lymphoma
